Addressing low BP in HF patients is complex, requiring individualized treatment strategies based on patient conditions, comorbidities, and HF etiology, as a one-size-fits-all approach is ineffective.

The massive loss of cardiomyocytes after cardiac injury and their subsequent replacement by fibrotic tissue is the major cause of heart failure, while the cardiomyocytes have limited proliferative capacity. Therefore, inducing resident cardiomyocytes to re-enter the cell cycle and progress through mitosis and cytokinesis is the most...

To regulate immune responses in heart failure (HF) through blocking the proinflammatory cytokine TNF-α failed despite promising preclinical data and success in autoimmune diseases. Recent discoveries, such as the production of the cytokine Oncostatin M in HF patients, which makes them unresponsive to anti-TNF-α treatment, highlight the need...

Single-cell technology has allowed researchers to probe tissue complexity and dynamics at unprecedented depth in health and disease. However, the generation of high-dimensionality single-cell atlases and virtual three-dimensional tissues requires integrated reference maps that harmonize disparate experimental designs, analytical pipelines,...

In our cohort, loop diuretic discontinuation was possible and safe in a large proportion of patients. The results should be interpreted with caution and cannot be extrapolated to a broader population of HF patients.